<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0083193#pone-0083193-g003" target="_blank">Figure 3</a> shows the probability of switching to a microbicide with different levels of HIV prevention effectiveness, pregnancy prevention effectiveness and price, according to whether she had used a condom or not in her last sex-act and predicted population level uptake. The choice is between the microbicide and a free female condom (with 95% protection against HIV and pregnancy), or neither. The light bars on the left are the probabilities for women who reported having used a condom in their last sex-act, on the darker bars on the right are the probabilities for women who had not used a condom in their last sex-act, the vertical line shows the predicted population level. The base case is modelled close to the CAPRISA 004 trial effectiveness results (54% effective against HIV and no pregnancy effectiveness). On the very left, it can be seen that an expensive microbicide with low prevention effectiveness would have a low probability of being chosen. As the product characteristics improve (towards the right of the figure), women find the product becomes more and more attractive relative to the female condom or what they did last time.</p
